What to do about problematic medication taking?
Welcome to another episode of BDI Briefs! Our aim with BDI Briefs is to take a brief look at important issues about the emotional side of diabetes.In this short discussion, Scott, Bill, and Susan explore problematic medication taking and what you can do about it. You may be surprised by some insights – I know I was! Enjoy! And please let us know what you think and what you’d like to hear more about. And remember to subscribe to BDI’s YouTube channel!
Detailed show notes and transcript
...
Source: Scott's Diabetes Blog - June 21, 2023 Category: Endocrinology Authors: Scott K. Johnson Tags: Blog Posts Source Type: blogs
Can You Follow A Keto Diet With Hypertension?
Conclusion
Navigating the maze of diet and health can indeed be a challenge. Especially when it comes to the trendy keto diet and its potential effects on hypertension. So, where do we land on the question, “Can you follow a keto diet with hypertension?”
From the studies we’ve reviewed and the real-life experiences we’ve heard, the answer is a cautious yes. It seems a well-managed keto diet could potentially benefit individuals with hypertension, mainly through weight loss, improved metabolic health, and lower blood sugar levels.
However, it’s not a one-size-fits-all approach. The key...
Source: The EMT Spot - June 21, 2023 Category: Emergency Medicine Authors: Michael Rotman, MD, FRCPC, PhD Tags: Blood Pressure Source Type: blogs
What happens when Rx price bubbles (such as on insulin) burst?
In the first half of 2023, Americans witnessed evidence of a rather fundamental shift in the manner pharma had traditionally opted to commercialize selected prescription drugs. Specifically, in March 2023,Lilly,Novo Nordisk andSanofi each announced they planned to slash insulin list prices for insulin. To do so, they would disintermediate PBMs from the transaction and " opt out " of the PBM commercialization channel.The decision wasn ' t really all that difficult; for years branded insulin-makers had been complaining that PBMs and other drug distribution system entities had been gobbling up an ever-larger share of their re...
Source: Scott's Web Log - June 19, 2023 Category: Endocrinology Tags: 2023 Source Type: blogs
Fight Aging! Newsletter, June 19th 2023
In conclusion, among Swedish middle-aged subjects, nearly two-thirds showed complete fatty degeneration of thymus on CT.
Age-Related Dysfunction of Water Homeostasis
https://www.fightaging.org/archives/2023/06/age-related-dysfunction-of-water-homeostasis/
Dehydration can be an issue in older people. As in every complex system in the body, the mechanisms by which hydration is regulated become dysfunctional with advancing age. Researchers here look at the brain region responsible for regulating some of the response to dehydration, cataloging altered gene expression in search of the more important mechan...
Source: Fight Aging! - June 18, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Forget about horses
You should know how to check your blood sugar if your CGM fails.You should know how to use an insulin pen if your pump fails.You should know how to use syringes if your insulin pen fails.But you can forget about horses.
Backup plans
I understand backup plans are a necessary part of living with diabetes. Whether you realize it or not, every time you do something, you think about the worst-case scenario with your diabetes and have a handful of solutions ready. It becomes automatic. Almos...
Source: Scott's Diabetes Blog - June 18, 2023 Category: Endocrinology Authors: Scott K. Johnson Tags: Blog Posts Source Type: blogs
Can You Practice Intermittent Fasting With Hypertension?
Conclusion
So, to revisit our core question: Can you practice intermittent fasting if you have hypertension?
Current evidence leans towards a positive answer, as long as it is done responsibly and under professional supervision.
However, it’s essential to understand that diet, while crucial, is just one aspect of hypertension management.
Regular health checkups, appropriate medication (if prescribed), and overall lifestyle adaptations all play integral roles in managing this condition successfully.
Read also: Best Foods, Herbs And Spices To Lower Blood Pressure
Reference
Effects of intermittent f...
Source: The EMT Spot - June 17, 2023 Category: Emergency Medicine Authors: Michael Rotman, MD, FRCPC, PhD Tags: Blood Pressure Source Type: blogs
Notes from the 2023 Age-Related Disease Therapeutics Summit
The former Longevity Therapeutics conference series was renamed to the Age-Related Disease Therapeutics Summit and held its fifth event recently in San Francisco. It was a smaller meeting than in past years, perhaps a result of the recent downturn in the global financial and investment environment. Few investors were present. Nonetheless, one can usually learn something interesting from the presenting biotech founders and executives. I took a few notes while I was there to present on progress at Repair Biotechnologies, and they follow in the order of the conference program.
Birget Schilling from the Buck Institute f...
Source: Fight Aging! - June 16, 2023 Category: Research Authors: Reason Tags: Longevity Industry Source Type: blogs
Sandoz/Gan & Lee Now Has Applications for Glargine, Lispro and Aspart Insulin Biosimilars on File with FDA, Expect them to come to market in early 2024.
Five years ago, back on December 19, 2018, Swiss pharmaceutical giant Novartis Pharma AG quietly issued a press release (seehttps://www.globenewswire.com/news-release/2018/12/19/1669194/0/en/Sandoz-enters-into-commercialization-and-supply-agreement-for-insulin-biosimilars-anticipating-growing-demand-as-diabetes-burden-rises.html for the release itself) on behalf of the company ' s business unit known as Sandoz. Specifically, Novartis said that its Sandoz generics unit planned to introduce biosimilars, or near-copy, versions of Sanofi ' s Lantus (glargine), Novo Nordisk ' s Novolog (aspart), and Eli Lilly ' s Humalog (lispr...
Source: Scott's Web Log - June 16, 2023 Category: Endocrinology Tags: 2023 Biosimilar biosimilars Gan & Lee insulin Sandoz Source Type: blogs
Free Download of The Capitol Forum's Report: " Exclusive Drug Dealing: Anticompetitive Practices in the Pharmaceutical Supply Chain "
In 2020, I wrote a blog post entitled " It ' s the Rx rebates, stupid! " (seehttps://blog.sstrumello.com/2020/09/its-rx-rebates-stupid.html for the post) in which I revealed the reason everyone was overpaying for insulin was because of rebating paid by insulin-makers to secure PBM formulary placement. Novo Nordisk revealed to its investors that it was spending 74% of its gross U.S. sales in the form of legally-exempted rebate kickbacks paid to PBMs. The good news is thanks to a series of actions by a number of different parties, the insulin PBM rebate price bubble finally burst whenLilly, followed byNovo Nordisk and thenSa...
Source: Scott's Web Log - June 11, 2023 Category: Endocrinology Tags: 2023 Exclusive Drug Dealing: Anticompetitive Practices in the Pharmaceutical Supply Chain report The Capitol Forum Source Type: blogs
Fight Aging! Newsletter, June 12th 2023
In this study, we investigated the effect of NXP032 on neurovascular stabilization through the changes of PECAM-1, PDGFR-β, ZO-1, laminin, and glial cells involved in maintaining the integrity of the blood-brain barrier (BBB) in aged mice. NXP032 was orally administered daily for 8 weeks. Compared to young mice and NXP032-treated mice, 20-month-old mice displayed cognitive impairments in Y-maze and passive avoidance tests. NXP032 treatment contributed to reducing the BBB damage by attenuating the fragmentation of microvessels and reducing PDGFR-β, ZO-1, and laminin expression, thereby mitigating astrocytes and microglia ...
Source: Fight Aging! - June 11, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Leading with the Trailing Edge: Facilitating Patient Choice for Insulin Products
Robin Feldman (University of California), Leading with the Trailing Edge: Facilitating Patient Choice for Insulin Products, UC San Francisco Working Paper (2023): Insulin prices have risen sharply in recent decades, despite the passage of a century since its inception. Insulin... (Source: HealthLawProf Blog)
Source: HealthLawProf Blog - June 11, 2023 Category: Medical Law Authors: Katharine Van Tassel Source Type: blogs
Looking Back at the Growth and Maturation of the Field of Aging Research
A great deal has changed in these last few decades in the field of aging research. From the 60s onward to the 90s, aging research was increasingly characterized by a philosophy of "look but don't touch", an effort to distance academia from the growing anti-aging industry and its hype. It made itself a backwater science in which talk of intervention was aggressively discouraged by leaders in the field. Starting in the 90s, with studies showing significant life extension in lower animals following single gene mutations, it became impossible to ignore the potential to treat aging as a medical condition in humans.
Nonet...
Source: Fight Aging! - June 9, 2023 Category: Research Authors: Reason Tags: Healthy Life Extension Community Source Type: blogs
iLet Bionic Pancreas Cleared by FDA
The iLet Bionic Pancreas for use by type 1 diabetes patients has been cleared by the FDA and is now available commercially. The device is offered by Beta Bionics, a medtech company based in Massachusetts and California, but the underlying technology originally developed by researchers at Boston University. The system can be paired with a Bluetooth glucose monitor to deliver personalized insulin dosing every five minutes, and calculates doses based on past and current glucose levels and its experience of how the user reacted to previous insulin doses. The technology has a personal origin story, as one of the researchers dro...
Source: Medgadget - June 8, 2023 Category: Medical Devices Authors: Conn Hastings Tags: Medicine artificial pancreas BetaBionics diabetes Type1 Source Type: blogs
Dexcom Pays PBMs Kickbacks to Exclude Rival CGMs; Senseonics Found a Way Around That
This week (on June 3, 2023), there was an interestingannouncement from the Maryland-based medical device startupSenseonics, Inc. that UnitedHealthcare will begin providing coverage for theEversense E3 CGM System effective July 1, 2023 for people with Type 1 and insulin-requiring Type 2 diabetes. You may recall that Senseonics received a cash-infusion financial lifeline from Ascensia Diabetes Care back on August 10, 2020 (see the news release for that athttps://www.businesswire.com/news/home/20200810005677/en/Senseonics-Announces-Strategic-Collaboration-with-Ascensia-Diabetes-Care for more) when that company effectively pai...
Source: Scott's Web Log - June 7, 2023 Category: Endocrinology Tags: 2023 Ascensia bribes CGM Eversense Formulary Exclusion kickbacks PBM Senseonics Source Type: blogs
Fight Aging! Newsletter, June 5th 2023
In conclusion, higher BMR might reduce lifespan. The underlying pathways linking to major causes of death and relevant interventions warrant further investigation.
Betting Against Progress Turns Out Poorly, But Can Work in the Short Term in a Slow Field
https://www.fightaging.org/archives/2023/06/betting-against-progress-turns-out-poorly-but-can-work-in-the-short-term-in-a-slow-field/
Setting oneself up as a spokesperson for "we will not achieve this goal", as the fellow noted here is choosing to do, is a bet against technological progress. A glance at any few decade period in the past two hundred yea...
Source: Fight Aging! - June 4, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
